EMEA-003179-PIP01-22 - paediatric investigation plan

sugemalimab

Key facts

• Active substance:
  sugemalimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0194/2022
• PIP number:
  EMEA-003179-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of lung cancer
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  10/06/2022
• Compliance check done:
  No

Decision

P/0194/2022: EMA decision of 10 June 2022 on the granting of a product specific waiver for sugemalimab (EMEA-003179-PIP01-22)

Adopted Reference Number: EMA/251179/2022